Literature DB >> 24535556

Emerging immunotherapies for rheumatoid arthritis.

Gary Reynolds1, Faye A H Cooles1, John D Isaacs2, Catharien M U Hilkens2.   

Abstract

Novel treatments in development for rheumatoid arthritis target 3 broad areas: cytokines, cells, and signaling pathways. Therapies from each domain share common advantages (for example previously demonstrated efficacy, potential long-term immunomodulation, and oral administration respectively) that have stimulated research in each area but also common obstacles to their development. In this review recent progress in each area will be discussed alongside the factors that have impeded their path to clinical use.

Entities:  

Keywords:  anti-chemokine therapy; anti-cytokine therapy; biologics; cellular therapy; immunotherapy; rheumatoid arthritis; small molecule inhibitors

Mesh：

Substances：

Year:  2014        PMID： 24535556      PMCID： PMC4896612          DOI： 10.4161/hv.27910

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  192 in total

1.  Genzyme backs Osiris, despite Prochymal flop.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2009-11       Impact factor: 54.908

Review 2.  Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis.

Authors:  Eugen Feist; Gerd R Burmester
Journal:  Rheumatology (Oxford)       Date:  2013-02-01       Impact factor: 7.580

3.  Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1.

Authors:  D L Tuttle; J K Harrison; C Anders; J W Sleasman; M M Goodenow
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collagen-induced arthritis.

Authors:  Gabriel Criado; Egle Simelyte; Julia J Inglis; David Essex; Richard O Williams
Journal:  Arthritis Rheum       Date:  2009-05

5.  The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients.

Authors:  J W van der Heijden; R Oerlemans; W F Lems; R J Scheper; B A C Dijkmans; G Jansen
Journal:  Clin Exp Rheumatol       Date:  2009 Jan-Feb       Impact factor: 4.473

6.  PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis.

Authors:  Silvia Hayer; Noreen Pundt; Marvin A Peters; Christina Wunrau; Inga Kühnel; Katja Neugebauer; Simon Strietholt; Jochen Zwerina; Adelheid Korb; Josef Penninger; Leo A B Joosten; Steffen Gay; Thomas Rückle; Georg Schett; Thomas Pap
Journal:  FASEB J       Date:  2009-09-04       Impact factor: 5.191

7.  Frequency of Th17 CD4+ T cells in early rheumatoid arthritis: a marker of anti-CCP seropositivity.

Authors:  Irene Arroyo-Villa; María-Belén Bautista-Caro; Alejandro Balsa; Pilar Aguado-Acín; Laura Nuño; María-Gema Bonilla-Hernán; Amaya Puig-Kröger; Emilio Martín-Mola; María-Eugenia Miranda-Carús
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

8.  Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.

Authors:  Shouvik Dass; Andy C Rawstron; Edward M Vital; Karen Henshaw; Dennis McGonagle; Paul Emery
Journal:  Arthritis Rheum       Date:  2008-10

9.  Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis.

Authors:  Heather R Conti; Fang Shen; Namrata Nayyar; Eileen Stocum; Jianing N Sun; Matthew J Lindemann; Allen W Ho; Justine Hoda Hai; Jeffrey J Yu; Ji Won Jung; Scott G Filler; Patricia Masso-Welch; Mira Edgerton; Sarah L Gaffen
Journal:  J Exp Med       Date:  2009-02-09       Impact factor: 14.307

Review 10.  Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005.

Authors:  Alan Tyndall; Ulrich A Walker; Andrew Cope; Francesco Dazzi; Cosimo De Bari; Willem Fibbe; Serena Guiducci; Simon Jones; Christian Jorgensen; Katarina Le Blanc; Frank Luyten; Dennis McGonagle; Ivan Martin; Chiara Bocelli-Tyndall; Giuseppina Pennesi; Vito Pistoia; Constantino Pitzalis; Antonio Uccelli; Nico Wulffraat; Marc Feldmann
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156
View more
  6 in total

1.  Vasoactive intestinal peptide is required in the maintenance of immune regulatory competency of immune regulatory monocytes.

Authors:  L Guan; D Yu; G-H Wu; H-J Ning; S-D He; S-S Li; T-Y Hu; G Yang; Z-Q Liu; H-Q Yu; X-Z Sun; Z-G Liu; P-C Yang
Journal:  Clin Exp Immunol       Date:  2019-01-30       Impact factor: 4.330

Review 2.  The Interrelationship Between Diabetes, IL-17 and Bone Loss.

Authors:  Zhen Huang; Xiyan Pei; Dana T Graves
Journal:  Curr Osteoporos Rep       Date:  2020-02       Impact factor: 5.163

3.  Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States.

Authors:  Manish Patel; Jufu Chen; Sara Kim; Shikha Garg; Brendan Flannery; Zaid Haddadin; Danielle Rankin; Natasha Halasa; H Keipp Talbot; Carrie Reed
Journal:  Emerg Infect Dis       Date:  2020-04-29       Impact factor: 6.883

Review 4.  Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis.

Authors:  Noha Mousaad Elemam; Suad Hannawi; Azzam A Maghazachi
Journal:  Immunotargets Ther       Date:  2020-03-09

5.  Exercise Exacerbates the Transcriptional Profile of Hypoxia, Oxidative Stress and Inflammation in Rats with Adjuvant-Induced Arthritis.

Authors:  Susana Aideé González-Chávez; Celia María Quiñonez-Flores; Gerardo Pavel Espino-Solís; José Ángel Vázquez-Contreras; César Pacheco-Tena
Journal:  Cells       Date:  2019-11-22       Impact factor: 6.600

Review 6.  Basic Mechanisms of JAK Inhibition.

Authors:  Chung Ma Lin; Faye Ah Cooles; John D Isaacs
Journal:  Mediterr J Rheumatol       Date:  2020-06-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.